Niowave Signs Long-Term Agreement to Supply Actinium-225 to Novartis

Niowave Inc., an American isotope producer, has signed a long-term supply agreement to deliver actinium-225 to Novartis, NucNet reported on February 24, 2026. The deal was first announced in a Niowave press release issued earlier in February, and the NucNet coverage confirmed the companies have formalized the arrangement.

The Feb 24, 2026 NucNet item makes the supply relationship public after Niowave’s initial February release, establishing Niowave as a named source of actinium-225 for Novartis. Niowave’s role as an American isotope producer is central to the announcement, and the press release issued earlier in February served as the basis for the NucNet report that the long-term agreement is in place.

Under the arrangement reported by NucNet, Niowave will deliver actinium-225, commonly written as Ac-225, to Novartis over the term of the contract. The companies did not release additional scheduling or volume details in the material referenced by NucNet on February 24, 2026, making the public disclosure on that date the clearest confirmation to date of the commercial relationship between Niowave and Novartis.

The February disclosures put Niowave and Novartis on the record for a sustained supply relationship for Ac-225 as of late February 2026. Industry watchers tracking isotope supply chains now have a named vendor-buyer pairing to follow, documented first by Niowave’s early-February press release and then by NucNet’s February 24, 2026 coverage. Expect Niowave and Novartis to be the sources of any subsequent announcements that add delivery schedules, production capacity numbers, or clinical program links tied to the agreement.